FOLH1 and neoplasm: Due to the fast clearance in blood and particularly insufficient dose delivery to tumor of small molecule compounds 177Lu/225Ac-PSMA-617, there have been long-term efforts in developing a general strategy which can effectively prolong the compounds’ half-life in vivo.